AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Breztri Aerosphere by Quarter
Breztri Aerosphere (budesonide/glycopyrronium/formoterol) — US product sales ($M) ($M)
AstraZeneca Breztri Aerosphere: $161M in Q2 2026, up 9.5% from a year earlier.
Latest, Q2 2026
161
Period ended Jun 30, 2026
Change on a year earlier
+9.5%
147 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below
Where the Q2 2026 figure comes from
“|| Breztri | | 346 | | 22 | | 20 | | 161 | | 9 | | 93 | | 43 | | 35 | | 62 | | 36 | | 31 | | 30 | | 23 | | 26”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up breztri Aerosphere
Cite this data
StockData. (2026). AstraZeneca Breztri Aerosphere ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-breztri-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.